Research Article
Prognostic Value of Intratumor Metabolic Heterogeneity Parameters on 18F-FDG PET/CT for Patients with Colorectal Cancer
Table 1
Baseline clinicopathological and PET information of subjects.
| | Variables | Values |
| | Gender | | Male | 114 (60.6%) | | Female | 74 (39.4%) | | Age, year | 65 (55–75) | | Location | | Right colon | 59 (31.4%) | | Left colon | 64 (34.0%) | | Rectum | 65 (34.6%) | | Pathological type | | Adenocarcinoma | 159 (84.6%) | | MAC/SRC | 29 (15.4%) | | Degree of differentiation. | | Low | 44 (23.4%) | | Median | 137 (72.9%) | | High | 7 (3.7%) | | Measured tumor length (cm) | 4.90 ± 1.66 | | T Stage | | T1-2 | 37 (19.7%) | | T3-4 | 151 (80.3%) | | Regional lymph nodes | | N– | 85 (45.2%) | | N+ | 103 (54.8%) | | Distant metastasis | | M– | 129 (68.6%) | | M+ | 59 (31.4%) | | Nerve invasion | | Negative | 148 (78.7%) | | Positive | 40 (21.3%) | | Tumor thrombus | | Negative | 135 (71.8%) | | Positive | 53 (28.2%) | | Stage, AJCC | | I | 25 (13.3%) | | II | 45 (23.9%) | | III | 59 (31.4%) | | IV | 59 (31.4%) | | Type of surgery | | Radical surgery | 129（68.6%） | | Palliative surgery | 59（31.4%） | | CEA (ng/ml) | 6.10 (2.77–21.84) | | CA19-9 (U/ml) | 17.17 (8.02–50.26) | | Parameters of PET | | SUVmax | 15.43 (11.98–20.91) | | SUVpeak | 10.67 (8.35–14.76) | | SUVmean | 8.91 (6.97–11.62) | | MTV (ml) | 12.17 (7.30–22.29) | | TLG (g) | 112.03 (62.88–214.86) | | HI-1 | 0.23 (0.21–0.24) | | HI-2 | 10.57 (6.05–19.21) |
|
|
MAC, mucinous adenocarcinoma; SRC, signet ring cell carcinoma; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; SUV, standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis; HI, heterogeneity index.
|
